Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly
Diabetes Care · 2026
DOI: 10.2337/dc25-2041 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2026. Verfasst von Ashok A Ganeshalingam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Research Unit, Department of Endocrinology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Insulin Resistance, Insulin-Secreting Cells, Antipsychotic Agents, Schizophrenia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Region Sjælland, Steno Diabetes Center Zealand, Aase og Ejnar Danielsens Fond.
Abstract (Originalsprache)
OBJECTIVE To examine the effects of semaglutide on insulin sensitivity, insulin resistance, and β-cell function and explore whether these changes were mediated by weight loss in overweight or obese individuals with schizophrenia and prediabetes receiving second-generation antipsychotics. RESEARCH DESIGN AND METHODS In this 30-week, double-blind trial, 154 participants were randomized to semaglutide (n = 77) or placebo (n = 77); 141 (91.5%) completed the study. Baseline and end-of-study assessments included fasting glucose, insulin, C-peptide, HOMA2 of β-cell function, HOMA2 of insulin sensitivity, HOMA of insulin resistance, and body weight. RESULTS Participants (56% women, mean age 38.3 years) provided complete insulin data in 131 cases. Compared with placebo, semaglutide significantly reduced fasting glucose (−0.87 mmol/L [95% CI −1.15, −0.59]; P < 0.001), improved insulin sensitivity (8.60 [5.82, 13.65]; P = 0.001), and lowered insulin resistance (−0.69 [−1.00, −0.20]; P = 0.006). Mean weight loss was 9.2 kg and mediated improvements in insulin sensitivity (estimate 7.82; P = 0.01) and insulin resistance (estimate −0.75; P = 0.01). Nonsignificant trends were observed toward reduced fasting insulin (−52.3 pmol/L; P = 0.11) and C-peptide (−182.9 pmol/L; P = 0.096), with a modest, nonsignificant increase in β-cell function (8.10; P = 0.19). CONCLUSIONS Semaglutide significantly improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and promoted substantial weight loss in patients with antipsychotic-induced metabolic disturbances. Weight loss partly mediated the metabolic improvements, while β-cell function remained largely unchanged. These findings support semaglutide as a potential strategy for mitigating metabolic dysfunction in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Endocrine Research Unit, Department of Endocrinology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark.
- Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
- Research Unit for Clinical Psychopharmacology, Psychiatry West in Region Zealand, Slagelse, Denmark.
- Child and Adolescent Psychiatry Odense, Mental Health Services in the Region of Southern Denmark, Odense, Denmark.
- Psychiatric Research Unit, Copenhagen University Hospital-Psychiatry Region Zealand, Slagelse, Denmark.
ORCID-Profile: Ashok A Ganeshalingam
Förderung
- Region Sjælland
- Steno Diabetes Center Zealand
- Aase og Ejnar Danielsens Fond
- Novo Nordisk Fonden
- Steno Diabetes Center Odense
Zitieren
APA
Ganeshalingam, A. A., Uhrenholt, N., Arnfred, S., Gæde, P., Pedersen, A. K., Bilenberg, N., & Frystyk, J. (2026). Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care. https://doi.org/10.2337/dc25-2041
Vancouver
Ganeshalingam AA, Uhrenholt N, Arnfred S, Gæde P, Pedersen AK, Bilenberg N, et al. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care. 2026. doi:10.2337/dc25-2041
BibTeX
@article{Ganeshalingam2026,
author = {Ganeshalingam, Ashok A and Uhrenholt, Nicolai and Arnfred, Sidse and Gæde, Peter and Pedersen, Andreas K and Bilenberg, Niels and Frystyk, Jan},
title = {Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc25-2041}
}
EUVIMED